Hematopoietic cell kinase (HCK) (HCK)

Hematopoietic cell kinase (HCK) is a non-receptor tyrosine kinase belonging to the Src family, predominantly expressed in hematopoietic cells such as myeloid and B-lymphoid lineages (UniProt P08631). It functions as a key signaling mediator for various cell surface receptors, including G protein-coupled receptors, integrins, and cytokine receptors, thereby regulating essential processes like phagocytosis, cell adhesion, and pro-inflammatory cytokine production (PubMed: 25639461). In oncology, HCK is frequently upregulated in myeloid leukemias and certain solid tumors, where it contributes to malignant transformation and drug resistance by activating survival pathways like STAT3 and PI3K/Akt (PubMed: 30249031). The target is also relevant in infectious diseases, as it is hijacked by the HIV-1 Nef protein to enhance viral replication (PubMed: 11836300). Therapeutic strategies often involve small-molecule inhibitors; however, due to the high structural conservation among kinase domains, these drugs frequently interact with 'off-target' kinases, leading to complex safety profiles (PubMed: 29431145). This polypharmacology can be beneficial for multi-kinase inhibition in complex diseases but also poses risks of adverse effects like pleural effusion or cardiotoxicity. Consequently, drug development efforts focus on balancing HCK potency with selectivity against other kinases to minimize these off-target interactions.

Other names

Hematopoietic cell kinasep59-HCKp61-HCKJTK9Tyrosine-protein kinase HCK

Inhibition of tyrosine kinase activity through ATP-competitive binding to the catalytic domain.